CTOs on the Move

Seton Imaging

www.setonimaging.com

 
Seton Imaging is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Buffalo, NY. To find more information about Seton Imaging, please visit www.setonimaging.com
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

OnPoint Medical Diagnosis

OnPoint Medical Diagnosis is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Minneapolis, MN. To find more information about OnPoint Medical Diagnosis, please visit www.onpointmd.com

Transcend Services

Transcend Services, Inc. (Transcend) provides medical transcription services to the healthcare industry. The Company provides two primary medical transcription options for customers: the provision of transcription services and technology using the

Kansas City Internal Medicine

Kansas City Internal Medicine is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hollister

Hollister Incorporated is an independently-owned global company that develops, manufactures and markets healthcare products, servicing over 90 countries. From the earliest days of our company, there has been a strong sense of community—a connection to people. That connection is embedded in the very fabric of our company, and as we continue to develop new products and services, we are focused on meeting the healthcare needs of people throughout the global community.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.